Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

Using Xpert MTB/RIF.

Mark P Nicol1, Andrew Whitelaw, Stevens Wendy

  • 1Division of Medical Microbiology, Department of Clinical Laboratory Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa ; National Health Laboratory Service, South Africa.

Current Respiratory Medicine Reviews
|October 4, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early versus Late Ventricular Intervention Study (ELVIS) in post-hemorrhagic ventricular dilatation: Bayesian reanalysis of brain injury and outcomes.

Pediatric research·2026
Same author

Characterization of <i>Ornithobacterium hominis</i> colonization dynamics and interaction with the nasopharyngeal microbiome in a South African birth cohort.

Microbial genomics·2026
Same author

Shotgun metagenomic profiling of bacterial microbiomes, metagenome-assembled genomes and antimicrobial resistance in respiratory and blood samples from Gambian children with pneumonia.

Research square·2026
Same author

Corrigendum: <i>Corynebacterium drakensteinense</i> sp. nov., isolated from the nasopharynx of a healthy South African infant.

International journal of systematic and evolutionary microbiology·2026
Same author

Optimisation of the sampling method for skin microbiome studies in healthy children: a pilot cohort study.

Frontiers in microbiomes·2026
Same author

<i>Corynebacterium drakensteinense</i> sp. nov., isolated from the nasopharynx of a healthy South African infant.

International journal of systematic and evolutionary microbiology·2026
Same journal

The Basement Membrane Zone in Asthma: The Supracellular Anchoring Network.

Current respiratory medicine reviews·2022
Same journal

Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis.

Current respiratory medicine reviews·2018
Same journal

Choline Triggers Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Infected with <i>Pseudomonas aeruginosa</i>.

Current respiratory medicine reviews·2018
Same journal

An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.

Current respiratory medicine reviews·2018
Same journal

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience.

Current respiratory medicine reviews·2017
Same journal

Fibrocytes in the Pathogenesis of Chronic Fibrotic Lung Disease.

Current respiratory medicine reviews·2016
See all related articles

The Xpert MTB/RIF test accurately detects tuberculosis and rifampicin resistance but shows lower sensitivity for smear-negative cases. Cost-effectiveness needs further demonstration for widespread use in high-burden countries.

Area of Science:

  • Microbiology
  • Molecular Diagnostics
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a global health challenge, necessitating rapid and accurate diagnostic tools.
  • Rifampicin resistance is a critical factor in TB treatment regimens.
  • Current diagnostic methods face limitations in speed, accuracy, and accessibility.

Purpose of the Study:

  • To evaluate the Xpert MTB/RIF assay for simultaneous detection of tuberculosis and rifampicin resistance.
  • To assess the performance characteristics of Xpert MTB/RIF, particularly in smear-negative TB cases.
  • To explore the suitability and constraints of Xpert MTB/RIF implementation in resource-limited settings.

Main Methods:

  • The study involved the Xpert MTB/RIF assay, an automated real-time polymerase chain reaction (PCR) test.
Keywords:
Cost-effectivenessXpert MTB/RIF.detectiondiagnosisrifampicintuberculosis

More Related Videos

Quantifying X-Ray Fluorescence Data Using MAPS
14:58

Quantifying X-Ray Fluorescence Data Using MAPS

Published on: February 17, 2018

Synchrotron X-ray Microdiffraction and Fluorescence Imaging of Mineral and Rock Samples
10:12

Synchrotron X-ray Microdiffraction and Fluorescence Imaging of Mineral and Rock Samples

Published on: June 19, 2018

Related Experiment Videos

Last Updated: May 7, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

Quantifying X-Ray Fluorescence Data Using MAPS
14:58

Quantifying X-Ray Fluorescence Data Using MAPS

Published on: February 17, 2018

Synchrotron X-ray Microdiffraction and Fluorescence Imaging of Mineral and Rock Samples
10:12

Synchrotron X-ray Microdiffraction and Fluorescence Imaging of Mineral and Rock Samples

Published on: June 19, 2018

  • Performance was evaluated through clinical studies assessing accuracy for TB detection and rifampicin resistance.
  • Consideration was given to automation, sample processing, and practical implementation challenges.

    • Main Results:

    • Xpert MTB/RIF demonstrated excellent accuracy in detecting tuberculosis and rifampicin resistance in clinical evaluations.
    • The test exhibited reduced sensitivity in identifying smear-negative tuberculosis cases.
    • Automation facilitates potential use in resource-limited settings, but practical constraints exist.

    Conclusions:

    • Xpert MTB/RIF is a highly accurate diagnostic tool for tuberculosis and rifampicin resistance.
    • Further research is needed to address its sensitivity limitations for smear-negative TB.
    • Demonstrating cost-effectiveness is crucial for scaling up Xpert MTB/RIF in high-burden countries.